pipeline-prospector-insert-v1
X

Find Novel Oncology Drugs in Preclinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GNOS-PV02,Pembrolizumab,INO-9012

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            Geneos Therapeutics' personalized neoantigen-targeting vaccine, GNOS-PV02, will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALT-702

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 23, 2020

            Details:

            Tumor regression and overall survival in the ALT-702 + anti-CTLA4 group was markedly better than either agent alone.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tumor Suppressor Candidate 2 gene,Osimertinib

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            The U.S FDA has granted Fast Track Designation for Genprex’s Oncoprex™ immunogene therapy in combination with EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NEO-STC-01

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: BioNTech

            Deal Size: $67.0 million Upfront Cash: $67.0 million

            Deal Type: Acquisition January 16, 2020

            Details:

            This acquisition to expand BioNTech's capabilities and strengthens its immunotherapy pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Monoclonal antibody-based therapy

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 16, 2020

            Details:

            This additional investment allows AgilVax to continue generating compelling preclinical data with their monoclonal antibody-drug conjugates targeting SLC7A11 (xCT).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WP1244

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            The agreement grants CNS Pharmaceuticals the right to develop and commercialize WP1244, for the potential treatment of primary and metastatic brain cancers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoid-like molecules

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: AXIM Biotechnologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 09, 2020

            Details:

            AXIM® Biotechnologies, has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech as a wholly-owned subsidiary.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MBT5,Temozolomide

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2020

            Details:

            This new discovery offers the potential to develop novel therapeutics for difficult-to-treat cancers, based on peptides encoded in the mitochondrial genome.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Onvatilimab

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Curis

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 07, 2020

            Details:

            ImmuNext will develop and commercialize anti-VISTA antibodies for the treatment of cancer, including ImmuNext's lead compound, CI-8993 (formerly JNJ-61610588).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BDTX-189

            Therapeutic Area: Oncology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: J.P. Morgan Securities

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: IPO January 03, 2020

            Details:

            The company’s plans for the IPO cash include financing Phase 1/2 tests of BDTX-189 and advancing preclinical development of its glioblastoma drug.

            PharmaCompass